Lorlatini（Lorlatinib）, manufactured by TLPH, was officially approved for marketing on September 1, 2021, following approval from the Food and Drug Department (FDD) of the Lao Ministry of Health. The approved Lao version of lorlatinib, sold as Lorlatini, comes in 25mg and 100mg versions.

Lorlatinib was formally approved by the US FDA on November 2, 2018, for the treatment of anaplastic lymphoma kinase (ALK) -positive metastatic non-small cell lung cancer (NSCLC). As a novel, reversible and potent small-molecule inhibitor of ALK and ROS1, lorlatinib has a strong inhibitory effect on known ALK resistance mutations, so it is known as the "third generation ALK inhibitor".

TLPH has always been driven by the needs of patients, and has been making technological breakthroughs, successfully imitating loratinib and putting it on the market. At this point, ASEAN Pharma has a full line of ALK inhibitor products, including crizotinib, ceritinib, alectinib, brigatinib and lorlatinib.